LMR Partners LLP Invests $1.59 Million in 10x Genomics, Inc. (NASDAQ:TXG)

LMR Partners LLP acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 70,303 shares of the company’s stock, valued at approximately $1,587,000. LMR Partners LLP owned about 0.06% of 10x Genomics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after buying an additional 371 shares in the last quarter. GAMMA Investing LLC increased its holdings in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after buying an additional 1,265 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in 10x Genomics during the third quarter worth $35,000. First Horizon Advisors Inc. increased its holdings in shares of 10x Genomics by 74.1% in the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock valued at $37,000 after purchasing an additional 808 shares during the last quarter. Finally, Covestor Ltd increased its holdings in shares of 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after purchasing an additional 873 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Barclays cut their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. UBS Group lowered their price objective on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Jefferies Financial Group raised 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Monday, July 22nd. Leerink Partners started coverage on shares of 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 target price for the company. Finally, The Goldman Sachs Group cut their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.19.

Insider Buying and Selling at 10x Genomics

In other news, CFO Justin J. Mcanear sold 2,961 shares of 10x Genomics stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now owns 143,242 shares in the company, valued at approximately $3,227,242.26. This trade represents a 2.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the sale, the insider now owns 345,704 shares of the company’s stock, valued at approximately $7,788,711.12. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,061 shares of company stock valued at $316,794 in the last quarter. 10.03% of the stock is currently owned by corporate insiders.

10x Genomics Stock Down 1.2 %

Shares of 10x Genomics stock opened at $13.18 on Tuesday. 10x Genomics, Inc. has a 1 year low of $12.96 and a 1 year high of $57.90. The stock has a fifty day moving average price of $18.25 and a 200-day moving average price of $20.26.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. The company had revenue of $151.65 million during the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.51) EPS. As a group, equities research analysts expect that 10x Genomics, Inc. will post -1.4 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.